KBY Biotech Indexv0.0.34
Search
← Pipeline|BGN-3859

BGN-3859

Approved
By BeiGene
Source: Trial-derived·Trials: 1
Modality
ERT
MOA
CD47i
Target
PSMA
Pathway
Proteasome
ALSMyelofibrosisACC
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
~Oct 2018
→ ~Jan 2020
Phase 3
~Apr 2020
→ ~Jul 2021
NDA/BLA
~Oct 2021
→ ~Jan 2023
Approved
Apr 2023
→ Jun 2027
ApprovedCurrent
NCT06450957
1,713 pts·ACC
2023-04→2027-06·Terminated
1,713 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2027-06-071.2y awayPh3 Readout· ACC
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
Approved
Termina…
Catalysts
Ph3 Readout
2027-06-07 · 1.2y away
ACC
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT06450957ApprovedACCTerminated1713Safety
Competitors (10)
DrugCompanyPhaseTargetMOA
NirarelsinJohnson & JohnsonPhase 2PRMT5CD47i
CevizanubrutinibJohnson & JohnsonPreclinicalFcRnCD47i
CeviglumideRocheNDA/BLAB7-H3CD47i
NVS-1475NovartisPhase 2MeninCD47i
AZN-3724AstraZenecaPreclinicalPSMABCMA ADC
AZN-6294AstraZenecaPhase 2/3APOC3CD47i
DoxacageneSanofiApprovedPSMASHP2i
ZenonesiranGSKPreclinicalDLL3CD47i
GSK-2051GSKPhase 1PSMAEGFRi
AMG-7379AmgenPreclinicalDLL3CD47i